NCT04478877

Brief Summary

In this study, meningioma organoids will be established from patients' tissues and the characterization of the organoid will be performed.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started May 2020

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 23, 2020

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

July 16, 2020

Completed
5 days until next milestone

First Posted

Study publicly available on registry

July 21, 2020

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2023

Completed
Last Updated

September 7, 2023

Status Verified

September 1, 2023

Enrollment Period

3.3 years

First QC Date

July 16, 2020

Last Update Submit

September 6, 2023

Conditions

Meningioma

Outcome Measures

Primary Outcomes (1)

  • Whole exome sequencing data

    DNA extracted from patient tumor tissue and patients-derived organoids will be perform whole exome sequencing for genetic characterization.

    7 days

Secondary Outcomes (1)

  • Immunostaining

    7 days

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with meningioma admitted to Prince Wales Hospitals neurosurgical services

You may qualify if:

  • Adult patients (aged \>18 years) with meningioma
  • Admission into Prince Wales hospitals neurosurgical services
  • Patients with surgical needs of meningioma removal

You may not qualify if:

  • \. Patients (or next-of-kin as appropriate) refuse to participate into the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Surgery, The Chinese University of Hong Kong

Hong Kong, Hong Kong

Location

Biospecimen

Retention: SAMPLES WITH DNA

Meningioma tumor sample

MeSH Terms

Conditions

Meningioma

Condition Hierarchy (Ancestors)

Neoplasms, Nerve TissueNeoplasms by Histologic TypeNeoplasmsNeoplasms, Vascular TissueMeningeal NeoplasmsCentral Nervous System NeoplasmsNervous System NeoplasmsNeoplasms by SiteNervous System Diseases

Study Officials

  • George KC Wong

    Chinese University of Hong Kong

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Professor

Study Record Dates

First Submitted

July 16, 2020

First Posted

July 21, 2020

Study Start

May 23, 2020

Primary Completion

August 31, 2023

Study Completion

August 31, 2023

Last Updated

September 7, 2023

Record last verified: 2023-09

Locations

HK(1)